Optiscan Unveils InSpecta™ to Transform Veterinary Diagnostics

Optiscan’s Strategic Leap into Veterinary Medicine

Optiscan Imaging Ltd (ASX, OIL) has taken a significant step in diversifying its product portfolio with the reveal of InSpecta™, a novel microscopic imaging device designed specifically for veterinary medicine. This launch aligns with the company’s broader growth strategy to tap into the high-growth veterinary sector, particularly the companion animal segment, which is both lucrative and rapidly expanding.

Built on Optiscan’s proprietary imaging technology, InSpecta™ is compact, rugged, and portable, designed to function seamlessly in diverse environments, from clinical offices to rural fieldwork. Its real-time, non-invasive imaging capabilities promise to enhance diagnostic accuracy and treatment effectiveness for a wide range of animals, addressing a critical gap in veterinary diagnostics.

Market Potential and Industry Impact

The US veterinary market alone was valued at nearly US$12 billion in 2022 and is forecasted to grow at an 8.7% compound annual growth rate through 2030. With millions of companion animals such as dogs and cats requiring advanced medical care, the demand for innovative diagnostic tools is substantial. InSpecta™ aims to meet this demand by offering veterinarians a device that improves surgical precision, diagnostic speed, and overall patient outcomes.

Beyond companion animals, the device’s applicability extends to equine and other veterinary sectors, potentially transforming care standards across species. By integrating this technology, veterinary professionals can expect to streamline workflows and elevate the quality of care delivered.

Clinical Validation and Regulatory Pathway

InSpecta™ is currently undergoing testing at the University of Minnesota College of Veterinary Medicine, a key partner in Optiscan’s veterinary initiative. These trials will provide critical clinical data to support regulatory submissions, a process that Optiscan is actively refining alongside its commercial strategy. The company anticipates that veterinary device regulations, which differ from human medical devices, may facilitate earlier market entry.

The device’s upcoming showcase at the American College of Veterinary Internal Medicine conference in Louisville, Kentucky, scheduled for June 19-21, 2025, will provide a platform to engage with veterinary professionals and gather further industry feedback.

Looking Ahead

Optiscan CEO Dr Camile Farah emphasized the collaborative design process behind InSpecta™, highlighting positive responses from veterinary experts and the device’s broad applicability for both in vivo and ex vivo uses. As the company continues to refine regulatory and commercial plans, it is poised to position InSpecta™ as a leading tool in microscopic veterinary imaging.

This development not only broadens Optiscan’s addressable market but also signals a promising new chapter in its evolution as a medical imaging innovator.